Immune complex removes receptors from stem cells to protect against cancer, preclinical study finds
A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing ...
thecardiologyadvisor.com5h
Survey Shows Nurses Seek More Training in Advanced Therapy Medicinal Products
Researchers surveyed nurses at EBMT centers to explore their training needs relating to ATMPs, local procedures, and self-assessed priority ranking for ATMP training. Nurses reported a need for ...
Drug in clinical trials for breast cancer could also treat some blood cancers
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...
FiercePharma4h
Gilead's Kite taps longtime Amgen alum as new global commercial head
Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...
News Medical on MSN6h
Drug in breast cancer trials shows potential for treating blood cancers
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...
Armed robbery in Revesby8h
Trial Drug for Breast Cancer May Treat Blood Cancers
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of ...
Managed Healthcare Executive3h
Investigational Breast Cancer Drug Demonstrates Potential Benefit in Treating AML and Other Blood Cancers
The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.
The Pharma Letter4h
With tislelizumab, BeiGene brings immunotherapy to more patients in Europe
This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.
T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
Future Market Insights5h
Global Hematology Diagnostic Industry to Reach USD 2.0 Billion by 2033 at a 9.9% of CAGR
The global hematology diagnostic market is projected to grow from USD 780.0 million in 2023 to USD 2.0 billion by 2033, at a ...
2-Day Webinar: Global Hematological Rare Disease Alliance
Piera Cutino Hematology Campus TAMPA, FL, UNITED STATES, January 15, 2025 /EINPresswire / -- San Rocco Therapeutics announces the GLOB ...